airPharma Signs Agreement With Britannia Pharmaceuticals Limited To Bring Novel Asthma Treatment To Market
10/19/2005 5:12:07 PM
airPharma and Britannia Pharmaceuticals Limited today announced that they have signed a global licensing agreement in which airPharma will develop AP0016, a dry powder formulation of Britannia's synthetic surfactant, Pumactant. Under the terms of the agreement, airPharma will initiate a clinical program to study the drug's efficacy for seasonal allergic asthma, followed by additional respiratory indications such as perennial allergic asthma and chronic obstructive pulmonary disease (COPD). airPharma will also assume control of regulatory and marketing initiatives for AP0016 as well as activities related to the eventual commercialization of the product worldwide, except for the United Kingdom and Ireland, which will remain under Britannia's management.
comments powered by